MedPath

All-comer registry for immunocardiology and cardiometabolic diseases Aache

Recruiting
Conditions
I20
I21
I22
I23
I24
I25
I46
I63
I64
I50
Registration Number
DRKS00025716
Lead Sponsor
niversitätsklinikum Aachen – Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin (Med. Klinik I)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
400
Inclusion Criteria

Patients with cardiovascular risk profiles who were fasting at the time of inclusion.

Exclusion Criteria

1. glucocorticoid/cortisone use (oral, intravenous - Not: topical, inhalation) and/or other immunosuppressive medication (except colchicine).
2. condition following solid organ transplantation or being on a waiting list for solid organ transplantation
3. active/chronic or recently treated malignant disease within the last 5 years
- Not: non-metastatic basal cell carcinoma of the skin
4. acute/active inflammatory disease of infectious and non-infectious nature
- e.g. infectious: bacterial disease (e.g. bacterial urinary tract infection, tuberculosis), viral disease (e.g. HIV/AIDS, viral hepatitis, COVID-19), fungal disease, parasitic disease
- e.g. non-infectious: sarcoidosis and other granulomatous diseases
5. acute episode of inflammatory bowel disease (Crohn's disease, ulcerative colitis) within the last 24 months
6. autoimmune diseases
- Not: diabetes mellitus, type 1 and/or Hashimoto's thyroiditis
7. acute or chronic disease of the hematopoietic system (including lymphoproliferative disorders)
8. final stage liver disease
9. active drug abuse
- Not: alcohol abuse
10. pregnancy and/or lactation
11. persons who are institutionalized by court or administrative order
12. persons who are in a dependent or employment relationship with the investigator
13. simultaneous participation in another clinical trial
14. patients who are unwilling or unable to understand and comply with the instructions of the personnel
15. taking an investigational drug 30 days prior to the start of the project
16. patients who are incapable of giving consent and/or are unable to understand the nature, significance and scope of the research project and to give their consent in writing

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survey of endpoints as part of a follow-up (electronic, telephone) 2x every six months after discharge, then annually. Various separate, primary endpoints:<br>- All-cause mortality<br>- Triple, cardiovascular endpoint (3P MACE)<br>- cardiovascular death<br>- nonfatal myocardial infarction<br>- nonfatal stroke<br>- hospitalization for unstable angina<br>- hospitalization for coronary revascularization (PTCA of any type - with and without stent implantation and/or coronary artery bypass grafting)<br>- hospitalization for heart failure
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath